drugset
drugset / Trial / NCT03892616

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

NCT03892616 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of a single dose of BI 1358894 administered as tablet formulation 2 (TF2a, TF2b) under fasted conditions compared with the tablet formulation 1 (TF1) of BI 1358894 under fed conditions following oral administration and to investigate the effect of food on the exposure with TF2 (TF2a, TF2b).

Timeline

Start
2019-04-08
Primary completion
2019-07-03
Completion
2019-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule 100 mg Oral

Indications

No indication recorded.